T2 Biosystems Announces FDA 510(k) Submission for the T2Biothreat Panel
The T2Biothreat Panel detects six biothreat pathogens and runs on the FDA-cleared T2Dx Instrument LEXINGTON,…
News
T2 Biosystems Announces FDA 510(k) Submission for the T2Biothreat Panel
The T2Biothreat Panel detects six biothreat pathogens and runs on the FDA-cleared T2Dx Instrument LEXINGTON,…
Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
Webcast to be held on Monday, June 5, 2023 at 8:00 a.m. ET WALTHAM, Mass….
Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
Webcast to be held on Monday, June 5, 2023 at 8:00 a.m. ET WALTHAM, Mass….
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m….
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m….
Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
SEATTLE, May 23, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing…
Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
SEATTLE, May 23, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing…
BrightInsight Named Leader in the Healthcare IoT Solutions Industry with Frost & Sullivan’s 2023 Global Company of the Year Award
The best-in-class BrightInsight Platform accelerates the time to market for patient apps that enable biopharma…
BrightInsight Named Leader in the Healthcare IoT Solutions Industry with Frost & Sullivan’s 2023 Global Company of the Year Award
The best-in-class BrightInsight Platform accelerates the time to market for patient apps that enable biopharma…
Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery
-Appointment expected to aid advancement of Theriva’s discovery program and strengthen collaboration with the Institut…
Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery
-Appointment expected to aid advancement of Theriva’s discovery program and strengthen collaboration with the Institut…
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director
REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director
REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
GeneType featured on U.S. National TV to raise Breast Cancer Awareness
GeneType featured on the Balancing Act Balance Act Set with Dr. Carolynn Young and Dr….
GeneType featured on U.S. National TV to raise Breast Cancer Awareness
GeneType featured on the Balancing Act Balance Act Set with Dr. Carolynn Young and Dr….
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
First FGF21 analog to enter Phase 3 development SAN FRANCISCO, May 23, 2023 (GLOBE NEWSWIRE)…
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
First FGF21 analog to enter Phase 3 development SAN FRANCISCO, May 23, 2023 (GLOBE NEWSWIRE)…
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer…
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer…